An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 22 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 19 Feb 2016 Planned End Date changed from 1 Nov 2017 to 1 Nov 2019, according to ClinicalTrials.gov record.
- 19 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.